Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prebet

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Expert Opinion on Investigational Drugs|January 4, 2011
Vorinostat in acute myeloid leukemia and myelodysplastic syndromesThomas Prebet, Norbert Vey
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Trends in Clinical Investigation for Myelodysplastic SyndromesThomas Prebet, Amer Zeidan
Therapeutic Advances in Hematology|August 22, 2019
Insights into novel emerging epigenetic drugs in myeloid malignanciesNamrata S Chandhok, Thomas Prebet
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2011
Treatment of acute promyelocytic leukemia for older patientsThomas Prebet, Steven D Gore
Current Opinion in Hematology|January 11, 2022
Azacitidine maintenance in AML post induction and posttransplantJan Philipp Bewersdorf, Thomas Prebet, Lohith Gowda
Therapeutic Advances in Hematology|November 26, 2020
Emerging treatment options for patients with high-risk myelodysplastic syndromeJan Philipp Bewersdorf, Hetty Carraway, Thomas Prebet
Leukemia & Lymphoma|December 10, 2019
Hypomethylating agent based combinations in higher risk myelodysplastic syndromeNamrata S Chandhok, Russell Lewis, Thomas Prebet
Expert Opinion on Investigational Drugs|January 26, 2016
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromesMaximilian Stahl, Steven D Gore, Norbert Vey, et al.
Blood Reviews|May 11, 2016
Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?Aziz Nazha, Thomas Prebet, Steven Gore, et al.
Leukemia & Lymphoma|September 23, 2016
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomingsBrian Ball, Amer Zeidan, Steven D Gore, et al.
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Expert Opinion on Investigational Drugs|January 4, 2011
Vorinostat in acute myeloid leukemia and myelodysplastic syndromesThomas Prebet, Norbert Vey
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Trends in Clinical Investigation for Myelodysplastic SyndromesThomas Prebet, Amer Zeidan
Therapeutic Advances in Hematology|August 22, 2019
Insights into novel emerging epigenetic drugs in myeloid malignanciesNamrata S Chandhok, Thomas Prebet
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2011
Treatment of acute promyelocytic leukemia for older patientsThomas Prebet, Steven D Gore
Current Opinion in Hematology|January 11, 2022
Azacitidine maintenance in AML post induction and posttransplantJan Philipp Bewersdorf, Thomas Prebet, Lohith Gowda
Therapeutic Advances in Hematology|November 26, 2020
Emerging treatment options for patients with high-risk myelodysplastic syndromeJan Philipp Bewersdorf, Hetty Carraway, Thomas Prebet
Leukemia & Lymphoma|December 10, 2019
Hypomethylating agent based combinations in higher risk myelodysplastic syndromeNamrata S Chandhok, Russell Lewis, Thomas Prebet
Expert Opinion on Investigational Drugs|January 26, 2016
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromesMaximilian Stahl, Steven D Gore, Norbert Vey, et al.
Blood Reviews|May 11, 2016
Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?Aziz Nazha, Thomas Prebet, Steven Gore, et al.
Leukemia & Lymphoma|September 23, 2016
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomingsBrian Ball, Amer Zeidan, Steven D Gore, et al.
Pageof 10